Multiple Sclerosis Drug Market Outlook:
Multiple Sclerosis Drug Market size was USD 27.8 billion in 2025 and is expected to reach USD 48.5 billion by the end of 2035, increasing at a CAGR of 6.2% during the forecast period, i.e., 2026-2035. In 2026, the industry size of multiple sclerosis drug is estimated at USD 29.3 billion.
The international patient pool in the multiple sclerosis (MS) drug market is significantly exceeding the 2.8 million mark, with an estimated 1 million cases recorded in the U.S., as stated by the National Multiple Sclerosis Society (NMSS). Additionally, the occurrence rate is increasing gradually from 5% to 7% annually, which is attributed to environmental factors and improved diagnostics. Additionally, the World Health Organization (WHO) has estimated that over 1.8 million people globally are thought to have MS. Therefore, all these factors are creating a positive impact on the overall market across different nations.
Moreover, current trends in the multiple sclerosis (MS) drug market reflect a lot of change in drug development, treatment options and aware of patient care. One specified trend is the increased use of biologic therapies. Monoclonal antibodies have become an important part of disease-modifying therapies (DMTs) for MS, including Ocrevus (ocrelizumab) and Tysabri (natalizumab). These biologics can target specific molecules that are involved in the immune attack of the central nervous system, which helps to define the pathogenesis of the disease. In addition to the biologics, we already have oral drugs like Gilenya and Tecfidera, which are something that is growing in popularity. Another trend is the increased effort concerning the progressive forms of MS. Progressive forms of MS have been much more difficult to treat. Ocrevus, of course, now has the approval for primary progressive MS, which is significant in establishing disease-modifying therapies.
